Israel Englander Lian Bio Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.33 - $4.6 $67,262 - $232,635	-50,573 Reduced 54.59%	42,074 $188,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $2.85 $284,337 - $452,716	-158,848 Reduced 63.16%	92,647 $211,000
Q1 2023 May 15, 2023	SELL	$1.57 - $2.66 $108,366 - $183,601	-69,023 Reduced 21.53%	251,495 $490,000
Q4 2022 Feb 14, 2023	BUY	$1.14 - $2.11 $125,545 - $232,370	110,128 Added 52.34%	320,518 $526,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $181,743 - $291,567	97,189 Added 85.86%	210,390 $419,000

1.09M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.